IL297664A - Degradation of proton tyrosine kinase by conjugation of btk inhibitors with e3 ligase ligand and methods of use - Google Patents

Degradation of proton tyrosine kinase by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Info

Publication number
IL297664A
IL297664A IL297664A IL29766422A IL297664A IL 297664 A IL297664 A IL 297664A IL 297664 A IL297664 A IL 297664A IL 29766422 A IL29766422 A IL 29766422A IL 297664 A IL297664 A IL 297664A
Authority
IL
Israel
Prior art keywords
compound
pct
mmol
tert
piperidin
Prior art date
Application number
IL297664A
Other languages
English (en)
Hebrew (he)
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of IL297664A publication Critical patent/IL297664A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL297664A 2020-04-30 2021-04-29 Degradation of proton tyrosine kinase by conjugation of btk inhibitors with e3 ligase ligand and methods of use IL297664A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020088322 2020-04-30
CN2021085369 2021-04-02
PCT/CN2021/090898 WO2021219070A1 (en) 2020-04-30 2021-04-29 Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Publications (1)

Publication Number Publication Date
IL297664A true IL297664A (en) 2022-12-01

Family

ID=78374077

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297664A IL297664A (en) 2020-04-30 2021-04-29 Degradation of proton tyrosine kinase by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Country Status (12)

Country Link
US (1) US20230167118A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146655A4 (cg-RX-API-DMAC7.html)
JP (2) JP7681038B2 (cg-RX-API-DMAC7.html)
CN (4) CN116589466B (cg-RX-API-DMAC7.html)
AU (1) AU2021264916B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019014A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172498A1 (cg-RX-API-DMAC7.html)
IL (1) IL297664A (cg-RX-API-DMAC7.html)
MX (1) MX2022013407A (cg-RX-API-DMAC7.html)
TW (2) TWI902789B (cg-RX-API-DMAC7.html)
WO (1) WO2021219070A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202209962B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146655A4 (en) * 2020-04-30 2024-07-31 BeiGene, Ltd. DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE
US20240246977A1 (en) * 2020-12-31 2024-07-25 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use
MX2023012981A (es) * 2021-05-03 2024-01-11 Nurix Therapeutics Inc Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
US20240287076A1 (en) * 2021-05-05 2024-08-29 Biogen Ma Inc. Compounds for targeting degradation of bruton's tyrosine kinase
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
AU2022300033A1 (en) * 2021-06-21 2024-01-18 Beone Medicines I Gmbh (r) -glutarimide crbn ligands and methods of use
CN119823111B (zh) * 2021-11-18 2026-05-05 正大天晴药业集团股份有限公司 稠合酰亚胺类衍生物
CN118414336A (zh) * 2021-12-30 2024-07-30 百济神州有限公司 通过使布鲁顿酪氨酸激酶(btk)抑制剂与e3连接酶配体缀合来降解btk及使用方法
CA3240051A1 (en) * 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
WO2024169871A1 (zh) * 2023-02-17 2024-08-22 江苏威凯尔医药科技有限公司 Btk抑制剂及其用途
CN118946561A (zh) * 2023-03-10 2024-11-12 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途
WO2025168081A1 (en) * 2024-02-09 2025-08-14 Beigene (Suzhou) Co., Ltd. Treating b-cell proliferative disorder with chimeric degradation activating compound
CN120623148A (zh) * 2024-03-11 2025-09-12 北京深势科技有限公司 一种c-Myc降解剂及其制备方法和用途
TW202543648A (zh) * 2024-04-19 2025-11-16 瑞士商百濟神州瑞士有限責任公司 包含布魯頓氏酪胺酸激酶降解劑之固體形式及其用途
WO2025232885A1 (en) * 2024-05-10 2025-11-13 Beigene (Suzhou) Co., Ltd. Preparation method of a bruton's tyrosine kinase degrader thereof
TW202610637A (zh) * 2024-07-10 2026-03-16 大陸商江蘇恆瑞醫藥股份有限公司 一種雜芳基類化合物、其製備方法及其在醫藥上的應用
WO2026021570A1 (en) * 2024-07-26 2026-01-29 Ascentage Pharma (Suzhou) Co., Ltd. Btk degrader and use thereof
US20260028345A1 (en) 2024-07-26 2026-01-29 Ascentage Pharma (Suzhou) Co., Ltd. Btk degrader and use thereof
WO2026119195A1 (en) 2024-12-04 2026-06-11 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising amorphous solid dispersion of bruton's tyrosin kinase degrader
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2026153355A1 (zh) * 2025-01-14 2026-07-23 江苏恒瑞医药股份有限公司 一种杂芳基类化合物、其制备方法及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013157021A1 (en) * 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
BR112015007513A2 (pt) * 2012-10-26 2017-07-04 Hoffmann La Roche inibidores de tirosina quinase de bruton
WO2015089327A1 (en) * 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN111936501B (zh) * 2018-03-26 2023-09-22 诺华股份有限公司 布鲁顿酪氨酸激酶降解剂
EP3774804A1 (en) * 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
EP4146655A4 (en) * 2020-04-30 2024-07-31 BeiGene, Ltd. DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE

Also Published As

Publication number Publication date
EP4146655A4 (en) 2024-07-31
AU2021264916A1 (en) 2022-11-03
KR20230003161A (ko) 2023-01-05
TW202608884A (zh) 2026-03-01
CA3172498A1 (en) 2021-11-04
WO2021219070A1 (en) 2021-11-04
TWI902789B (zh) 2025-11-01
TW202142542A (zh) 2021-11-16
CN116589466A (zh) 2023-08-15
ZA202209962B (en) 2023-05-31
US20230167118A1 (en) 2023-06-01
JP2023523130A (ja) 2023-06-02
JP7681038B2 (ja) 2025-05-21
CN116589467A (zh) 2023-08-15
CN116589466B (zh) 2025-08-15
BR112022019014A2 (pt) 2022-11-29
EP4146655A1 (en) 2023-03-15
AU2021264916B2 (en) 2026-05-21
JP2025122005A (ja) 2025-08-20
MX2022013407A (es) 2022-11-14
CN121159541A (zh) 2025-12-19
CN115485278A (zh) 2022-12-16

Similar Documents

Publication Publication Date Title
AU2021264916B2 (en) Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
JP7579816B2 (ja) HPK1阻害剤としてのピロロ[2,3-b]ピラジン及びその使用
CN114127067B (zh) 作为hpk1抑制剂的三环化合物及其用途
CN114929689B (zh) Bcl-2抑制剂
TW202246255A (zh) Cdk抑制劑及其使用方法
WO2021180103A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2020103896A1 (en) Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof
US20220281876A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
US12521440B2 (en) Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
WO2021032148A1 (en) Aminopyrazine compounds as hpk1 inhibitor and the use thereof
US20240246977A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use
US20240228497A1 (en) Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof
US20240342292A1 (en) Compounds for the Degradation of EGFR Kinase
US20240366770A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
EA050708B1 (ru) Деградация тирозинкиназы брутона (btk) посредством конъюгации ингибиторов btk с лигандом лигазы е3 и способы применения
EA046667B1 (ru) ПИРРОЛО[2,3-b]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРА HPK1 И ИХ ПРИМЕНЕНИЕ